<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01347411</url>
  </required_header>
  <id_info>
    <org_study_id>DIDAS</org_study_id>
    <nct_id>NCT01347411</nct_id>
  </id_info>
  <brief_title>Effectiveness of the Treatment With Continuous Positive Airway Pressure(CPAP)in Stable Heart Failure With Ejection Fraction More Than 45% and Sleep Disordered Breathing</brief_title>
  <official_title>Effectiveness of the Treatment With CONTINUOUS POSITIVE AIRWAY PRESSURE (CPAP) in Stable Heart Failure With Ejection Fraction More Than 45% and Sleep Disordered Breathing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Basque Health Service</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Basque Health Service</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The respiratory sleep disorders are a major cardiovascular risk factor. In fact there is
      enough scientific evidence that supports the association between apnea-hypopnea syndrome
      (SASH) and cardiovascular disease (hypertension, stroke, heart failure ....The objective of
      this study is to estimate the effectiveness of the continuous positive pressure airway (CPAP)
      in patient with chronic heart failure with normal ejection fraction but dyastolic dysfunction
      and sleep disordered breathing during the sleep.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients without diastolic dysfunction</measure>
    <time_frame>One year</time_frame>
    <description>number of patient without diastolic dysfunction defined by any of this parametres: TRI (isovolumetric relaxation time):&gt; 105 ms (&gt; 50 years),&gt; 100 ms (30-50 years). 2. Wave ratio E / A wave &lt;1 and deceleration time&gt; 220 ms (under 50) and E / A &lt;0.5 and deceleration time&gt; 280 ms (50 +). 3. Relationship between systolic and diastolic wave flow following pulmonary vein (S / D): S / D&gt; 1.5 (under 50) and S / D&gt; 2.5 (over 50). A wave velocity of pulmonary venous flow&gt; 35 cm / s. Flow propagation velocity by color M-mode &lt;45 cm / s. E wave peak velocity by DTI of the ring: Em &lt;5 cm / s</description>
  </primary_outcome>
  <primary_outcome>
    <measure>number of hospital admissions for any cause</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">420</enrollment>
  <condition>Heart Failure</condition>
  <condition>Sleep Respiratory Disorders</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CPAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with CPAP</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CPAP</intervention_name>
    <description>Treatment with CPAP</description>
    <arm_group_label>CPAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ejection fraction&gt; 45%, which also ruled out significant left ventricular dilation

          2. At least two abnormal indices of diastolic function.

        Exclusion Criteria:

          1. Not sinus rhytm

          2. Severe lung disease (FEV1 or FVC less than 50%)

          3. Significant valvular or congenital heart disease, primary

          4. Unstable angina, myocardial infarction or cardiac surgery within three months prior to
             inclusion

          5. Hypertrophic Cardiomyopathy

          6. Presence of significant psychiatric disorders.

          7. Severe Hypersomnia . (Epworth&gt; 20)

          8. Severe pulmonary hypertension measured by Doppler,

          9. Facial deformity and / or defect of nasal patency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2011</study_first_submitted>
  <study_first_submitted_qc>May 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2011</study_first_posted>
  <last_update_submitted>May 3, 2011</last_update_submitted>
  <last_update_submitted_qc>May 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Carlos Javier Egea Santaolalla</name_title>
    <organization>Hospital Txagorritxu</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

